Aim: Interleukin-17 (IL-17) family cytokines promote the host defence against mycobacterial infections. We have previously shown an association between IL17A variations and Bacillus Calmette-Guérin (BCG) osteitis. This paper evaluates the association of three IL17F polymorphisms with BCG osteitis after newborn vaccination.

Methods: IL17F rs763780, rs11465553 and rs7741835 single nucleotide polymorphisms (SNPs) were studied in 132 adults, who presented with BCG osteitis in infancy. The genotypes and minor allele frequencies (MAFs) were compared between cases and Finnish population-based controls (N = 99) from the 1000 Genomes Project, and MAFs were compared between cases and allele data of Finnish subjects from the large Genome Aggregation Database.

Results: There were no significant differences between former BCG osteitis patients and population-based controls in the IL17F rs763780 (wild 84.4% vs 84.8%), rs11465553 (86.4% vs 91.9%) or rs7741835 (65.7% vs 67.7%) genotypes. Homozygous variant genotypes were only present in 1.5%, 0.8% and 3.8% of cases, respectively. Likewise, MAFs of the three IL17F SNPs did not substantially differ from those of 11 252, 11 939 and 1371 Finnish subjects, respectively, from the available Genome Aggregation Database.

Conclusion: IL17F rs763780, rs11465553 and rs7741835 variations showed no association with the risk of BCG osteitis after newborn vaccination.

Download full-text PDF

Source
http://dx.doi.org/10.1111/apa.15574DOI Listing

Publication Analysis

Top Keywords

bcg osteitis
20
il17f rs763780
12
variations association
8
newborn vaccination
8
three il17f
8
osteitis newborn
8
rs763780 rs11465553
8
rs11465553 rs7741835
8
mafs compared
8
compared cases
8

Similar Publications

Adrenocorticotropic hormone (ACTH) therapy is effective for infantile epileptic spasms syndrome (IESS) but can induce immunosuppression. In Japan, Bacille Calmette-Guérin (BCG) vaccination, modified in 2013 to reduce osteitis/osteomyelitis risk, coincides with the peak onset age of IESS. This raises concerns about infection risks when administering ACTH therapy post-vaccination.

View Article and Find Full Text PDF

Osteitis of the radius after bacillus Calmette-Guèrin vaccination in international adopted children.

Minerva Pediatr (Torino)

October 2024

Unit of Infectious Diseases, Department of Pediatrics and Public Health Sciences, Regina Margherita Children's Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

View Article and Find Full Text PDF

Typical time courses and appearance of skin reactions at the site of Bacillus Calmette-Guérin vaccination for infants inoculated at 5-8 months of age.

Vaccine

February 2023

Department of Pediatrics, MacKay Children's Hospital and MacKay Memorial Hospital, Taipei, Taiwan; Department of Medicine, MacKay Medical College, New Taipei, Taiwan; MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan. Electronic address:

Background: Taiwan increased the Bacillus Calmette-Guerin (BCG) vaccination age from 24 h after birth to 5-8 months of age to lower BCG-related osteitis/osteomyelitis in 2016. However, the sequences of skin changes at the injection site and in the corresponding lymph nodes are unknown for infants vaccinated at an older age.

Methods: We prospectively collected the photographs of skin reactions within 6 months after vaccination.

View Article and Find Full Text PDF
Article Synopsis
  • Japan revised the recommended age for BCG vaccinations multiple times from under 6 months to 5-8 months due to rising cases of BCG-related osteitis/osteomyelitis since 2005.
  • Data on adverse events from BCG vaccinations in infants <1 year were collected from April 2013 to March 2017, comparing events in those vaccinated before and after reaching 6 months.
  • Findings showed a higher incidence of osteitis/osteomyelitis in infants vaccinated at <6 months, suggesting the age adjustment in 2013 likely helped reduce these adverse effects.
View Article and Find Full Text PDF

BCGosis is a rare complication of intravesical BCG immunotherapy as adjuvant therapy for urinary bladder cancer manifesting in the form of disseminated tuberculosis or organ-specific tuberculosis, rarely involving the vertebra. PSMA is overexpressed in prostate cancer but also expressed in a variety of benign and malignant conditions. We present a patient with incidental detection of abnormal uptake in a vertebral lesion during assessment of prostate cancer with 18F-PSMA PET/CT, subsequently proven to be vertebral osteitis, likely due to BCG immunotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!